Abdominal Aortic Aneurysm
Clinical Snapshot
Abdominal aortic aneurysm (AAA) is a focal, permanent dilation of the abdominal aorta to a diameter of at least 3.0 cm, or to at least 1.5 times the expected normal diameter for the patient — most commonly below the renal arteries (infrarenal). It develops silently over years to decades as the aortic wall weakens, and the large majority of AAAs cause no symptoms at all until either an elective repair decision is reached or the aneurysm ruptures.
Management of AAA rests on 2 separate tracks that run in parallel and should never be confused with one another. The surveillance track applies to every small, stable aneurysm below the size threshold for repair: regular size-based ultrasound follow-up, plus standard, individualized cardiovascular risk-factor management and smoking cessation — but critically, no medication has been proven to shrink an aneurysm or reliably slow its growth. This is a genuine and common misconception, corrected explicitly and in detail in Choose Initial Treatment below.[1][2] The repair track applies once the aneurysm reaches a size or growth-rate threshold, becomes symptomatic, or ruptures — a decision made by vascular surgery between endovascular (EVAR) and open surgical repair, not a pharmacotherapy escalation.[1]
Recognize the Condition
Most AAAs are found incidentally — on an ultrasound or CT ordered for an unrelated reason, on a screening ultrasound, or on physical examination as a pulsatile abdominal mass — rather than because the patient reports symptoms.
3 clinical presentations of AAA
Asymptomatic (unruptured)
The default presentation. Found incidentally or on screening ultrasound. May produce a pulsatile, expansile mass on deep abdominal palpation, though physical examination is an insensitive way to detect or exclude an AAA, especially in a patient with obesity — a normal abdominal exam never rules out an AAA on its own.
Symptomatic (unruptured)
New abdominal, flank, or back pain attributable to the aneurysm itself — often a constant, gnawing ache rather than the sudden, severe pain of rupture — without hemodynamic instability. This represents a change in the aneurysm (often rapid expansion or an impending or contained rupture) and is treated as an urgent, same-day vascular surgery problem, not a routine surveillance finding (see Red Flags & Refer).
Ruptured
A true surgical emergency. Classically presents with the triad of sudden, severe abdominal and/or back pain, a pulsatile abdominal mass, and hypotension — but all 3 features are present together in only a minority of patients, so the diagnosis must be considered in any older patient (especially a man with vascular risk factors) presenting with unexplained abdominal or back pain and hemodynamic instability, even without a known prior AAA diagnosis. A rupture may be initially contained by the retroperitoneum, temporarily stabilizing the patient, or free into the peritoneal cavity, which is rapidly fatal without immediate intervention.
Risk Factors
Non-modifiable
- Age 65 years or older — risk increases steadily with age.
- Male sex — men are affected substantially more often than women, though women who do develop an AAA carry a higher rupture risk at any given diameter (see Choose Initial Treatment).
- A first-degree relative (parent, sibling, or child) with a history of AAA — a substantially and independently increased risk that applies regardless of the relative's own age or sex, and that is not captured by the general population screening criteria below (see Special Populations).
- A personal history of a thoracic or other peripheral arterial aneurysm.
- A genetic connective tissue disorder — Marfan syndrome, vascular Ehlers-Danlos syndrome, or Loeys-Dietz syndrome (see Special Populations).
Modifiable
- Smoking, active or past — the single strongest modifiable risk factor for both developing an AAA and for its growth and rupture once present; a history of ever having smoked substantially raises risk even after the patient has quit.
- Hypertension.
- Dyslipidemia.
- Established atherosclerotic disease elsewhere — coronary artery disease, peripheral artery disease, or cerebrovascular disease.
- Chronic obstructive pulmonary disease, independent of shared smoking history.
A genuine exception worth knowing
Diabetes mellitus is, unusually among vascular risk factors, consistently associated with a lower risk of developing an AAA and with slower growth of an AAA that is already present — the opposite direction of its effect on essentially every other atherosclerotic condition covered elsewhere in this library. This does not change how diabetes itself is managed, and a patient with diabetes and an established AAA still needs the same standard surveillance and risk-factor approach as any other patient — but it is a genuinely counterintuitive, useful teaching point when discussing risk with a patient or colleague.[1]
Red Flags & Refer
Escalate immediately for any of the following — these are emergencies to be acted on directly, not findings to schedule for routine follow-up:
- Sudden, severe abdominal, flank, or back pain — especially with hypotension, syncope, or a known AAA — treat as a ruptured AAA until proven otherwise. Call for emergency transport immediately; in a hemodynamically unstable patient, do not wait for confirmatory imaging before activating an emergency response.[1]
- New abdominal, flank, or back pain in a patient with a known, previously stable AAA, even without instability — this can indicate rapid expansion or a contained (not yet free) rupture, and needs same-day vascular surgery assessment, typically with urgent CT angiography.[1]
- New tenderness to palpation over a previously non-tender, known AAA.
- An AAA that has reached or passed the size threshold for elective repair — 5.5 cm in men, 5.0 cm in women — refer for elective repair evaluation rather than simply continuing surveillance at the same interval.[1]
- Rapid growth — more than 1 cm over the past year, or more than 0.5 cm over the past 6 months — is itself an indication for referral and repair consideration, regardless of the absolute diameter.[1]
- A pulsatile abdominal mass newly discovered on physical examination in a patient without a documented AAA — obtain prompt ultrasound confirmation.
Assessment & Diagnosis
History
- Age, sex, and smoking history (current or ever) — the core criteria for whether screening is indicated (see Choose Initial Treatment).
- Family history of AAA in a first-degree relative, personal history of another arterial aneurysm, and features suggesting a connective tissue disorder (tall stature, joint hypermobility, skin or vascular fragility) — each independently changes the screening and surveillance approach (see Special Populations).
- Cardiovascular risk factors and established atherosclerotic disease.
- Character, onset, and location of any abdominal, flank, or back pain, and any hemodynamic symptoms (lightheadedness, syncope) — critical for distinguishing stable surveillance from a possible rupture (see Red Flags & Refer).
Physical examination
Palpate for a pulsatile, expansile abdominal mass, usually above the umbilicus given the infrarenal location of most AAAs — but treat a normal examination as reassuring only, never as a way to rule out an AAA, since sensitivity is limited and falls further as body habitus increases. Assess hemodynamic stability directly (pulse, blood pressure, mental status, skin perfusion) in any patient with abdominal or back pain and a known or suspected AAA.
Ultrasound — the primary tool for both screening and surveillance
Abdominal ultrasound is inexpensive, involves no radiation or contrast exposure, and is the recommended modality for both initial screening and ongoing surveillance of a known AAA. Measure the maximum anteroposterior and transverse diameter in both transverse and sagittal planes, using a consistent measurement convention (outer wall to outer wall) between studies — switching modality or measurement technique between surveillance scans can create the appearance of growth or stability that is not real, so use the same modality, and ideally the same reporting convention, from one surveillance study to the next.[1]
Surveillance intervals by diameter
| Maximum AAA diameter | Recommended surveillance interval |
|---|---|
| 3.0-3.9 cm | Every 3 years |
| 4.0-4.9 cm | Every 12 months |
| 5.0-5.4 cm | Every 6 months |
| Men 5.5 cm or larger; women 5.0 cm or larger; growth more than 1 cm/year (or more than 0.5 cm in 6 months); or new AAA-related symptoms | Refer to vascular surgery for repair evaluation instead of continuing surveillance alone |
CT angiography
Reserve CT angiography for confirming a suspected rupture, for pre-operative anatomic planning once a patient is being evaluated for repair, and for post-repair surveillance (see Monitoring & Follow-Up) — not for routine ongoing surveillance of a stable, small AAA, where ultrasound is preferred to avoid cumulative radiation and contrast exposure over what can be years of follow-up. Where contrast is required in a patient with reduced renal function, apply the same contrast-associated AKI prevention framework used throughout this platform (see Acute Kidney Injury).
Treatment Targets
- Prevent rupture — the single overriding goal of AAA management, achieved primarily through correctly timed elective repair rather than through medical therapy.
- Detect an AAA in the population most likely to benefit from finding it — men aged 65-80 — through appropriate one-time screening.
- Track growth reliably with a consistent surveillance schedule and measurement technique, so the repair threshold is reached and acted on rather than missed.
- Reduce the patient's overall cardiovascular risk (myocardial infarction, stroke, cardiovascular death) using standard, individualized criteria — not because it changes the aneurysm itself, but because AAA is a marker of systemic atherosclerosis carrying its own independent cardiovascular risk.
- Achieve complete smoking cessation — the one intervention genuinely shown to slow AAA growth.
- Choose the repair approach (EVAR or open) appropriate to the patient's anatomy, surgical risk, and preferences once a repair threshold is reached.
- Sustain appropriate lifelong surveillance after repair to detect endoleak, device migration, or another late complication before it becomes an emergency.
Choose Initial Treatment
Men aged 65-80 offer one-time screening ultrasound for AAA — a weak recommendation based on moderate-quality evidence, meaning the decision should still involve the patient's own preferences, but screening is appropriate for essentially every man in this age range regardless of smoking history, since the trials supporting screening were not stratified by smoking status and the CTFPHC did not issue a separate recommendation for smokers on that basis.[3][4]
Men older than 80 do not routinely screen — the risk of harm from an elective repair procedure in this age group outweighs the benefit of detection; individualize only for a healthy man without significant comorbidity who specifically wants to discuss it.[3]
Women, any age do not screen — this is a strong recommendation; AAA prevalence in women, and the risk of a repair procedure, together mean population screening does not show a net benefit in this group.[3]
First-degree relative (parent, sibling, or child) of a patient with AAA consider one-time ultrasound screening at age 65-75, or beyond 75 if the relative is otherwise in good health — regardless of their own sex or smoking history, since the elevated risk in this group is independent of both.[1]
Every patient under the repair threshold continue size-based ultrasound surveillance per the interval table in Assessment & Diagnosis, and pursue complete smoking cessation — the single intervention with genuine evidence of slowing AAA growth (see Non-Pharmacologic Treatment and Drug Tables).[1]
Do not start or intensify a statin, an ACE inhibitor or ARB, a beta-blocker, doxycycline, or another antibiotic specifically to slow AAA growth or reduce rupture risk — none of these has been shown to do so, and this is a genuinely common misconception worth correcting directly with patients and colleagues. The largest randomized trial of an antibiotic for this purpose, comparing doxycycline against placebo in patients with a small AAA, found no difference in aneurysm growth over 2 years.[2] Continue any of these medications when there is a separate, standard indication for it (hypertension, established cardiovascular disease, an ASCVD-risk-based statin indication) — but base that decision on the patient's overall cardiovascular risk profile using the criteria in Hypertension and Dyslipidemias, not on the presence of the aneurysm itself.[1]
Men 5.5 cm or larger, women 5.0 cm or larger, growth more than 1 cm/year (or more than 0.5 cm in 6 months), or new AAA-related symptoms refer to vascular surgery for elective repair evaluation rather than continuing surveillance at the same interval — obtain CT angiography for anatomic planning.[1]
Endovascular aneurysm repair (EVAR) preferred when the aneurysm's anatomy is suitable — lower perioperative morbidity and mortality and a faster recovery than open repair, at the cost of a higher long-term reintervention rate and a lifelong need for post-repair surveillance imaging to detect endoleak (see Monitoring & Follow-Up).[1]
Open surgical repair the alternative when anatomy is unsuitable for EVAR, or by patient/surgeon preference where both are reasonable options — higher perioperative morbidity, but more durable over the long term and without the same lifelong imaging-surveillance burden once the patient has recovered.[1]
Treat the diameter thresholds as a guide, not an absolute trigger applied identically to every patient — weigh the patient's surgical risk, life expectancy, frailty, and preferences explicitly in the repair decision, particularly in an older or frail patient near the threshold, rather than proceeding automatically once a number is reached (see Special Populations).
Treat sudden, severe abdominal or back pain with hypotension, or any hemodynamic instability in a patient with a known AAA, as a ruptured AAA until proven otherwise — activate an emergency vascular surgery response immediately.[1]
Permissive (hypotensive) hemostasis in the conscious, spontaneously breathing patient — restrict aggressive IV fluid resuscitation and accept a lower-than-normal blood pressure while still maintaining consciousness and vital organ perfusion, until bleeding is surgically controlled. Aggressive fluid resuscitation before control of the bleeding can raise pressure against an uncontrolled leak and worsen blood loss.[1]
EVAR preferred over open repair for ruptured AAA when anatomy is suitable and the patient's hemodynamic status tolerates the CT angiography needed for planning; open repair otherwise. A door-to-intervention time under 90 minutes is the target once rupture is suspected.[1]
Non-Pharmacologic Treatment
Smoking cessation — the single most effective non-drug intervention
Complete smoking cessation is the one intervention with genuine evidence of slowing AAA growth and reducing rupture risk, distinct from the pharmacologic options addressed in Choose Initial Treatment and Drug Tables, none of which has shown this effect. Address it at every visit using the full assessment and pharmacotherapy framework in Tobacco Use Disorder — this is one of the highest-yield interventions available for a patient with an AAA and should never be deferred while other aspects of care are addressed.
General cardiovascular risk-reduction measures
Address diet, physical activity, weight, diabetes, hypertension, and dyslipidemia using the non-pharmacologic measures in their own chapters (Hypertension, Dyslipidemias, Diabetes Mellitus, Obesity) — these reduce the patient's overall cardiovascular risk but, unlike smoking cessation, have not been shown to change the aneurysm's growth or rupture risk directly.
Physical activity
Regular, moderate physical activity is not restricted by the presence of an AAA and has not been shown to increase rupture risk — reassure a patient who is avoiding normal daily activity or exercise out of unfounded fear that this is not necessary. Discuss any planned very strenuous or competitive activity individually with the patient's vascular surgeon, particularly for a larger or more borderline aneurysm, rather than applying a blanket restriction to every patient under surveillance.
Ensure the next surveillance appointment is actually booked
Before the visit ends, confirm the next surveillance ultrasound is scheduled and that the patient understands why — a documented gap where a small AAA is found but no follow-up interval is ever booked is a common, preventable system failure, and it is the surveillance schedule itself, not a medication, that is protecting the patient between now and the next visit.
Repair itself is the definitive non-pharmacologic treatment
Once an AAA reaches the repair threshold, EVAR or open surgical repair — not escalation of any medication — is the treatment that actually addresses the aneurysm; see Choose Initial Treatment and Drug Tables.
Special Populations
Pregnancy
An AAA in a patient of reproductive age is rare, since it typically develops after decades of arterial wall degeneration, but when it does occur it is disproportionately associated with an underlying genetic connective tissue disorder (Marfan syndrome, vascular Ehlers-Danlos syndrome, Loeys-Dietz syndrome) rather than the typical atherosclerotic AAA covered by the rest of this chapter. Manage an AAA discovered in pregnancy jointly with maternal-fetal medicine and vascular surgery from the outset. A ruptured AAA in pregnancy is managed with the same emergency protocol described in Choose Initial Treatment — immediate emergency response and repair — regardless of gestational age, since maternal survival is also the best chance of fetal survival. Statins are contraindicated in pregnancy — see Dyslipidemias. ACE inhibitors and ARBs are also contraindicated in pregnancy — see Hypertension.
Breastfeeding
None of the medications discussed in this chapter is prescribed for the AAA itself (see Drug Tables) — where a statin, antihypertensive, or antiplatelet agent is used for an independent indication in a breastfeeding patient, follow the standard breastfeeding-compatibility guidance in Dyslipidemias and Hypertension rather than any AAA-specific consideration.
Older adults and frailty
Most patients with an AAA are older adults, and this is exactly the population in whom the diameter-based repair threshold should be treated as a guide rather than an automatic trigger. Explicitly weigh surgical risk, life expectancy, frailty, and the patient's own preferences before proceeding to repair in a frail or very elderly patient near the threshold — continued surveillance without repair (sometimes called watchful waiting) is a reasonable, guideline-consistent choice for a patient in whom the risk of the repair procedure itself is judged to exceed the risk of the aneurysm over their expected remaining lifespan. Ensure this group still receives explicit rupture-symptom education (see Red Flags & Refer) even when repair has been deferred, since they remain at ongoing rupture risk.
Genetic connective tissue disorders
Marfan syndrome, vascular Ehlers-Danlos syndrome, and Loeys-Dietz syndrome cause aortic aneurysms — often thoracic as much as or more than abdominal — at smaller diameters and younger ages than typical atherosclerotic AAA, and behave more aggressively. Manage a patient with a known or suspected connective tissue disorder under specialist (genetics and vascular/cardiac surgery) direction using disorder-specific size thresholds and surveillance intervals, not the general population-based criteria in this chapter.
First-degree relatives
A first-degree relative of a patient with AAA carries a meaningfully increased risk independent of their own age, sex, or smoking history — consider one-time ultrasound screening at age 65-75, or beyond 75 if they are otherwise in good health, even if they would not otherwise meet the general population screening criteria in Choose Initial Treatment.[1]
Renal impairment
Relevant mainly through CT angiography contrast exposure during pre-repair planning and post-EVAR surveillance (see Monitoring & Follow-Up) — apply the same contrast-associated AKI prevention framework used throughout this platform in a patient with reduced renal function (see Acute Kidney Injury), and favour ultrasound or a reduced-contrast protocol where it will still answer the clinical question.
Monitoring & Follow-Up
During surveillance (before repair)
- Follow the size-based interval table in Assessment & Diagnosis, using a consistent imaging modality and measurement convention from one study to the next.
- Confirm the next surveillance appointment is actually booked before the patient leaves — an AAA found but never followed up is a preventable system failure, not a rare one.
- Reinforce smoking cessation and standard, individualized cardiovascular risk-factor management at every visit.
- Reassess against the repair threshold and rapid-growth criteria at every surveillance scan, not only when the patient happens to mention symptoms.
- Give every patient under surveillance explicit rupture-symptom education — what sudden severe abdominal or back pain with lightheadedness means, and to seek emergency care immediately rather than waiting to discuss it at the next scheduled visit.
After endovascular repair (EVAR)
EVAR requires lifelong surveillance imaging that open repair does not, since a stent-graft can develop an endoleak, migrate, or the aneurysm sac can continue to enlarge despite an apparently successful procedure — this ongoing imaging burden is one of the genuine trade-offs against EVAR's lower perioperative risk (see Choose Initial Treatment). Image with CT angiography or duplex ultrasound at 1 month, 6 months, and 12 months after the procedure, then annually indefinitely.[1] Contrast-enhanced ultrasound is an emerging option at some centres to reduce a patient's cumulative radiation and contrast exposure over a lifetime of post-EVAR surveillance.
After open surgical repair
Open repair does not carry the same endoleak risk and generally does not require the same intensive, lifelong imaging surveillance once the patient has recovered — this durability is a genuine advantage of open repair over EVAR, weighed against its higher perioperative morbidity. Periodic follow-up remains appropriate at the treating surgeon's discretion to detect a late complication — anastomotic pseudoaneurysm, graft infection, or aortoenteric fistula — rather than being abandoned entirely.
Family screening
Use the diagnosis of a patient's own AAA as the trigger to discuss one-time screening in their first-degree relatives (see Special Populations) — this is easy to miss if the conversation focuses only on the index patient.
Common Errors to Avoid
- Starting or intensifying a statin, ACE inhibitor/ARB, beta-blocker, or antibiotic specifically to try to shrink or slow an AAA — none of these has been shown to do this; the one genuinely effective non-surgical intervention is smoking cessation.
- Trusting a normal abdominal examination to exclude an AAA — physical examination has limited sensitivity, especially in a patient with obesity, and is never a substitute for ultrasound when there is genuine clinical concern.
- Missing a screening opportunity in an eligible man aged 65-80 because he has never smoked — the CTFPHC's screening recommendation for this age group is not limited to patients who have smoked.
- Screening a woman, or a man over 80, outside the specific circumstances (family history, connective tissue disorder, individualized shared decision-making) where it remains reasonable.
- Forgetting to ask about a first-degree relative's AAA history, which independently changes the screening recommendation regardless of the patient's own age, sex, or smoking status.
- Finding a small AAA on incidental imaging and not scheduling the next surveillance interval before the patient leaves.
- Switching imaging modality or measurement technique between surveillance scans without accounting for it, and misreading the apparent change as true growth or stability.
- Treating the size threshold for repair as an absolute trigger rather than a guide, without weighing surgical risk, life expectancy, and preferences in an older or frail patient.
- Assuming post-EVAR surveillance can be relaxed once a patient looks and feels well — endoleak and sac enlargement are often clinically silent and are caught only by the scheduled imaging itself.
- Delaying an emergency response for sudden severe abdominal or back pain with hypotension in an older patient while waiting for confirmatory imaging.
- Over-resuscitating a hemodynamically unstable, conscious patient with suspected rupture using aggressive IV fluids before bleeding is surgically controlled, instead of using permissive hypotension.
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Cardiovascular Risk-Reduction Therapy (individualized — see the evidence note below)
None of the medications in this table has been shown to slow AAA growth or reduce rupture risk on its own. Prescribe each one only when the patient's overall cardiovascular risk profile independently indicates it, using the standard criteria in Hypertension and Dyslipidemias — not because the AAA is present.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Atorvastatin | High-intensity, if indicated: 40-80 mg PO daily | Myalgia, transaminase elevation | Avoid strong CYP3A4 inhibitors (amiodarone, azole antifungals, macrolides, protease inhibitors, verapamil/diltiazem) | See Dyslipidemias for the complete statin selection, dosing, and monitoring framework. Start only if independently indicated by standard ASCVD risk criteria. |
| Rosuvastatin | High-intensity, if indicated: 20-40 mg PO daily | Myalgia, transaminase elevation | Avoid strong CYP2C9 inhibitors; increased levels with cyclosporine | See Dyslipidemias. Start at 5 mg/day instead of 10 mg/day in select ancestry groups per that chapter, if indicated. |
| ASA | If indicated: 81 mg PO daily | GI upset, GI bleeding | Increased bleeding with anticoagulants and other antiplatelet agents | Only if independently indicated by standard cardiovascular criteria — not for the aneurysm itself. |
| Clopidogrel | If indicated: 75 mg PO daily | Bleeding, rash, diarrhea | PPI use may reduce efficacy | Only if independently indicated by standard cardiovascular criteria. |
Antihypertensive Therapy
Treat hypertension itself to the standard target described in Hypertension — no antihypertensive class, including ACE inhibitors and ARBs, has been shown to slow AAA growth or reduce rupture risk beyond the blood pressure control any effective agent provides. Select and dose the specific agent using the Hypertension chapter's own framework rather than a AAA-specific one, since none exists.
Explicitly Not Recommended for Slowing AAA Growth or Reducing Rupture Risk
Do not start any of the following specifically because of the AAA. Continue an agent only if it is independently indicated for another condition.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Doxycycline (or roxithromycin/another MMP-inhibiting antibiotic) | For AAA growth reduction: Not recommended — do not start for this purpose | GI upset, esophagitis, photosensitivity | Not applicable for this indication | The largest randomized trial (N-TA3CT) found no difference in 2-year aneurysm growth compared with placebo.<cite data-reference-id="17704a73-d6ae-4f07-80b2-e0cf99043f19"></cite> |
| Beta-blocker (e.g., metoprolol, propranolol) | For AAA growth reduction: Not recommended — do not start for this purpose | Bradycardia, hypotension, fatigue, bronchospasm | Additive bradycardia with diltiazem/verapamil/digoxin | Continue only if independently indicated (hypertension, prior MI, arrhythmia) — not shown to slow AAA growth or reduce rupture risk when started for that purpose alone. |
| ACE inhibitor or ARB (e.g., ramipril, losartan) | For AAA growth reduction specifically: Not recommended as a preferred class for this purpose | Cough (ACE inhibitor), hyperkalemia, hypotension | Hyperkalemia risk with potassium-sparing diuretics/supplements | Treat hypertension itself to standard target if present — not specifically recommended over another antihypertensive class for the aneurysm. |
Smoking Cessation Pharmacotherapy
The one intervention in this chapter with genuine evidence of slowing AAA growth is smoking cessation itself, not a drug directed at the aneurysm. See Tobacco Use Disorder for the complete first-line pharmacotherapy framework — varenicline, bupropion SR, and nicotine replacement therapy — and offer it to every patient who smokes at every visit.
Evidence note: the recommendation against using a statin, ACE inhibitor/ARB, beta-blocker, or antibiotic specifically to slow AAA growth is drawn from the current Society for Vascular Surgery AAA guideline, cross-checked against the largest randomized antibiotic trial.[1][2]
References
- The Society for Vascular Surgery Practice Guidelines on the Care of Patients with an Abdominal Aortic Aneurysm — Journal of Vascular Surgery (Chaikof EL, Dalman RL, Eskandari MK, et al.). J Vasc Surg 2018;67(1):2-77.e2
- Effect of Doxycycline on Aneurysm Growth Among Patients With Small Infrarenal Abdominal Aortic Aneurysms: A Randomized Clinical Trial — JAMA (Baxter BT, Matsumura J, Curci JA, et al.; N-TA3CT Investigators). JAMA 2020;323(20):2029-2038
- Recommendations on Screening for Abdominal Aortic Aneurysm in Primary Care — Canadian Task Force on Preventive Health Care. CMAJ 2017;189(36):E1137-E1145
- Screening for Abdominal Aortic Aneurysms in Canada: 2020 Review and Position Statement of the Canadian Society for Vascular Surgery — Canadian Journal of Surgery (Kapila V, Jetty P, Wooster D, Vucemilo V, Dubois L; Canadian Society for Vascular Surgery). Can J Surg 2021;64(5):E461-E466
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.